1. Home
  2. BOLT vs GRNQ Comparison

BOLT vs GRNQ Comparison

Compare BOLT & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLT
  • GRNQ
  • Stock Information
  • Founded
  • BOLT 2015
  • GRNQ 2013
  • Country
  • BOLT United States
  • GRNQ Malaysia
  • Employees
  • BOLT 52
  • GRNQ N/A
  • Industry
  • BOLT Biotechnology: Pharmaceutical Preparations
  • GRNQ EDP Services
  • Sector
  • BOLT Health Care
  • GRNQ Technology
  • Exchange
  • BOLT Nasdaq
  • GRNQ Nasdaq
  • Market Cap
  • BOLT 11.5M
  • GRNQ 11.3M
  • IPO Year
  • BOLT 2021
  • GRNQ 2018
  • Fundamental
  • Price
  • BOLT $6.01
  • GRNQ $1.35
  • Analyst Decision
  • BOLT Buy
  • GRNQ
  • Analyst Count
  • BOLT 4
  • GRNQ 0
  • Target Price
  • BOLT $34.00
  • GRNQ N/A
  • AVG Volume (30 Days)
  • BOLT 36.8K
  • GRNQ 822.2K
  • Earning Date
  • BOLT 11-11-2025
  • GRNQ 11-12-2025
  • Dividend Yield
  • BOLT N/A
  • GRNQ N/A
  • EPS Growth
  • BOLT N/A
  • GRNQ N/A
  • EPS
  • BOLT N/A
  • GRNQ N/A
  • Revenue
  • BOLT $4,167,000.00
  • GRNQ $3,256,679.00
  • Revenue This Year
  • BOLT N/A
  • GRNQ N/A
  • Revenue Next Year
  • BOLT N/A
  • GRNQ N/A
  • P/E Ratio
  • BOLT N/A
  • GRNQ N/A
  • Revenue Growth
  • BOLT N/A
  • GRNQ N/A
  • 52 Week Low
  • BOLT $4.59
  • GRNQ $0.80
  • 52 Week High
  • BOLT $14.36
  • GRNQ $2.50
  • Technical
  • Relative Strength Index (RSI)
  • BOLT 56.39
  • GRNQ 45.23
  • Support Level
  • BOLT $5.61
  • GRNQ $1.25
  • Resistance Level
  • BOLT $6.10
  • GRNQ $1.51
  • Average True Range (ATR)
  • BOLT 0.40
  • GRNQ 0.11
  • MACD
  • BOLT -0.01
  • GRNQ -0.01
  • Stochastic Oscillator
  • BOLT 49.80
  • GRNQ 20.49

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.

Share on Social Networks: